Apertura Gene Therapy
PrivateLast Round
Series A
Apr 26, 2022
Total Funding Raised
$67M
Company Overview
Apertura Gene Therapy operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in April 2022.
Apertura Gene Therapy is a biotechnology company that develops genetic medicines and next-generation AAV capsids designed to enable effective and selective gene delivery across the blood-brain barrier.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apertura Gene Therapy Comparables
Compare Apertura Gene Therapy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dyno Therapeutics | 84% | |
| Capsida Biotherapeutics | 84% | |
| Shape Therapeutics | 83% |
For institutional investors. Book with your work email.
Apertura Gene Therapy Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Apertura Gene Therapy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 12, 2026
Open Aperture provides researchers access to TfR1 CapX technology.
- Jan 1, 2026
Collaborating with Viralgen Vector Core to advance novel therapies.
For institutional investors. Book with your work email.
Apertura Gene Therapy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Apertura Gene Therapy's valuation, stock price, and market status.
Is Apertura Gene Therapy a public or private company?
Apertura Gene Therapy is a private company.
What is the current stock price of Apertura Gene Therapy?
Apertura Gene Therapy is a private company, so its shares have no public market price. Caplight tracks Apertura Gene Therapy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Apertura Gene Therapy worth (valuation)?
Valuation information for Apertura Gene Therapy is not publicly available.
Can I buy Apertura Gene Therapy stock?
Apertura Gene Therapy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Apertura Gene Therapy's last funding round?
Apertura Gene Therapy's most recent funding round was Series A on April 26, 2022.
Who are the main investors in Apertura Gene Therapy?
Key investors in Apertura Gene Therapy include Deerfield Management.
Will Apertura Gene Therapy IPO soon?
No public IPO plans have been announced for Apertura Gene Therapy.
How can I track Apertura Gene Therapy secondary market activity?
Caplight tracks bids, offers, and trades in Apertura Gene Therapy's shares on secondary markets.